ResearcherPeking University Cancer HospitalActive in the last 2 years

Changsong Qi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9157-3768; OpenAlex author ID A5043941211. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2023: 1 paper · 2024: 1 paper

Papers 2

Safety and Efficacy of CT041 in Patients With Refractory Metastatic Pancreatic Cancer: A Pooled Analysis of Two Early-Phase Trials. Co-author DOI 10.1200/jco.23.02314 ↗
CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer. Co-author DOI 10.1186/s13045-023-01491-9 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Lin Shen · 2 shared papers, 2023–2024 · strength 0.34
- Paper CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer. DOI 10.1186/s13045-023-01491-9 ↗
- Paper Safety and Efficacy of CT041 in Patients With Refractory Metastatic Pancreatic Cancer: A Pooled Analysis of Two Early-P… DOI 10.1200/jco.23.02314 ↗
Jun Zhou · 2 shared papers, 2023–2024 · strength 0.34
- Paper CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer. DOI 10.1186/s13045-023-01491-9 ↗
- Paper Safety and Efficacy of CT041 in Patients With Refractory Metastatic Pancreatic Cancer: A Pooled Analysis of Two Early-P… DOI 10.1200/jco.23.02314 ↗
Jun Zhang · 1 shared paper, 2024 · strength 0.17
- Paper Safety and Efficacy of CT041 in Patients With Refractory Metastatic Pancreatic Cancer: A Pooled Analysis of Two Early-P… DOI 10.1200/jco.23.02314 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.